Meiji Seika Pharma Co., Ltd engages in the manufacture and sale of ethical pharmaceuticals, agricultural chemicals, and veterinary drugs in Japan and internationally.
Address:4-16 Kyobashi 2-chome, Chuo-ku, Tokyo 104-8002, Japan
API/Biologics development and manufacturing
- API development phases/scales
- API process capabilities
- API process equipment
- Biologics development and manufacturing
Life Sciences Supplies/Reagents
- (24.Aug.2021) Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183, a Selective PDE4 Inhibitor for the Treatment of Psoriasis
- (10.Aug.2021) AstraZeneca's New Coronavirus Vaccine "Bakiszebria Intramuscular Injection"Notice Regarding the Start of Delivery
- (27.Jul.2021) Notice Regarding Transfer of DM Bio Shares
- (27.Jul.2021) Research and Development on the New β-Lactamase Inhibitor OP0595 (Nacubactam) -Interim Evaluation Results in the AMED CiCLE Project
- (22.Jul.2021) Intas Enters Into an Exclusive License Agreement With Meiji and Dong-A ST to Commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
- (24.Jun.2021) HUYABIO Announces HBI-8000 Brand Name of Hiyasta
- (11.Jun.2021) Announcement of New Release of Porcine Edema Disease Vaccine "Eco-Pork Shiga"
- (09.Jun.2021) About the Start of Joint Research and Development Between Kitasato Institute and Meiji Seika Pharma with the Aim of Creating a Breakthrough Therapy for COVID-19 Using a Next-Generation Ivermectin Derivative and Building a Foundation for Antiviral Drugs
- (02.Jun.2021) OrthogenRx Surpasses Sales of 1 Million in Syringes (Units)
- (28.May.2021) Notice Regarding the Release of the New Coronavirus (SARS-CoV-2) Antigen Rapid Test Kit "Check MR-COV19"
- (21.May.2021) Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis
- (06.May.2021) Concluded a Joint Research Agreement Between Industry and Academia on "Depression Prevention DX and Social Implementation Utilizing Kansei Brain Science"
- (01.Apr.2021) Notice of Conclusion of Sales Tie-Up Agreement with Rohto Pharmaceutical for New Coronavirus (SARS-CoV-2) Antigen Rapid Test Kit and Influenza Virus Antigen Rapid Test Kit
- (25.Mar.2021) KM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)
- (12.Mar.2021) Termination of Contract for Joint Promotion and Marketing Alliance for Chronic Obstructive Pulmonary Disease (COPD)
- (08.Mar.2021) Notice Regarding Manufacturing and Marketing Approval of "Bisoprolol Fumarate Tablet" Meiji "
- (25.Feb.2021) Announcement of Approval for Partial Change in Dosage and Administration of Acute Leukemia "Daunomycin Intravenous 20 Mg", an Antineoplastic Agent
- (15.Feb.2021) Notice Regarding Manufacturing and Marketing Approval of Generic Drugs
- (05.Feb.2021) Notice Regarding the Conclusion of a Business Consignment Contract with AstraZeneca for the Domestic Supply of the New Coronavirus Vaccine "AZD1222"
- (01.Feb.2021) Eisai to Launch Parkinson’s Disease Treatment Equfina in South Korea
- (25.Jan.2021) Dong-A ST, US FDA Approval for Phase 3 Clinical Trial Of'dMB-3115' for Chronic Plaque Psoriasis Treatment
- (21.Jan.2021) Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
- (06.Jan.2021) Notice of Start of Phase I Clinical Trial of Chronic GVHD Therapeutic Drug "ME3208"
- (05.Jan.2021) Meiji Seika Pharma Sets Up a New Subsidiary in the US